Monopar Therapeutics MNPR 深 滬
已收盤 08-07 16:00:00 美东时间
119.21
-1.000
-0.83%
華盛通- 最 高124.42
- 今 開121.85
- 成交量 22.33万股
- 最 低 118.04
- 昨 收 120.21
- 總市值 7.99亿
- 52周最高 124.82
- 市盈率 靜 --
- 換手率 3.33%
- 52周最低 29.18
- 委 比 -14.89%
- 總股本 669.91万
- 歷史最高 240.00
- 量 比 0.70
- 振 幅 5.31%
- 歷史最低 1.3695
- 每 手 1
- 風險率 19.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted the first completed sections of the NDA. If the completed NDA is accepted for fil...
07-22 20:02
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics Inc. has appointed seasoned commercial leaders to support the anticipated launch of its first product, ALXN1840, for Wilson disease, pending FDA approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, has joined the Board of Directors. Sharon Funk and Daniel Olmstead have been appointed as Senior Vice Presidents for Sales and Marketing, and Market Access, Distribution, and Patient Services, respe...
07-20 12:00
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗健康企业：革命医药（RVMD）、福泰制药（VRTX）与Monopar Therapeutics Inc（MNPR）
近期3名医疗领域分析师分别对3只美股医疗股给出看涨评级，相关标的及核心信息如下： 瑞沃医药（RVMD）：Needham分析师阿米·法迪亚给出买入评级，目标价...
06-30 10:32
分析师解读医疗健康企业：美敦力（MDT）、Monopar Therapeutics Inc（MNPR）与Bio-Techne（TECH）
医疗保健领域近期释放乐观信号，3位分析师分别对美敦力（MDT）、莫诺帕制药公司（MNPR）、Bio-Techne（TECH）给出看涨评级。 相关个股评级及核心数...
06-30 10:32
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Monopar Therapeutics announced new Phase 3 FoCus trial analyses for ALXN1840, showing significant neurologic and global clinical improvement in Wilson disease patients compared to standard therapy. Key findings include superior outcomes on the UWDRS and CGI-I scales, with better safety and tolerability. These results support Monopar's planned NDA submission for ALXN1840 in mid-2026.
06-26 20:05
美股牛股 | 特朗普政府加码量子计算！QNT涨超13%；Backblaze涨超43%，与CoreWeave签署一项3.35亿美元协议
特朗普政府加码量子计算！ARQQ大涨超35%，QNT涨超13%；Backblaze涨超43%，与CoreWeave签署一项3.35亿美元的数据存储协议>>
06-24 15:51
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics announced Phase 2 data for ALXN1840 at the EASL Congress 2026, showing stabilization of liver disease and improvement in neurological symptoms and quality of life for Wilson disease patients. The open-label trial involved 29 heavily pre-treated patients, with key findings including liver pathology stabilization, significant neurological and clinical improvements, and good tolerability. ALXN1840, a novel copper chelator, addre...
06-01 11:00
